奈达铂联合多西紫杉醇治疗晚期肺鳞癌的临床研究  

Clinical study on nedaplatin combined with docetaxel in the treatment of advanced lung squamous carcinoma

作　　者：杨静欢[1] 陈梅晞[1] 赵燕仪[2] 刘晓黎[1] 吕倩[1] 黄剑伟[1] 

机构地区：[1]桂林医学院附属医院呼吸内科,广西桂林541001 [2]桂林医学院附属医院肿瘤内科,广西桂林541001

出　　处：《华夏医学》2017年第4期29-32,共4页Acta Medicinae Sinica

基　　金：广西壮族自治区卫生与计划生育委员会计划课题项目资助(Z2016391)

摘　　要：目的:评价奈达铂联合多西紫杉醇治疗晚期肺鳞癌的疗效及安全性。方法:21例未接受过化疗治疗的晚期肺鳞癌的,所患NSCLC体积可测定的患者被纳入。患者接受多西紫杉醇(60 mg/m2)及奈达铂(80 mg/m2)治疗,在疗程第1天静脉给药,每3周1个疗程,共4个疗程。结果:采用多西紫杉醇及奈达铂治疗,缓解率为62%。中位无进展生存时间为7.4个月。中位存活时间为16.1个月,1年生存率为66.7%。最常见的不良反应为中性粒细胞减少(3/4级,86%)。非血液系统毒性反应相对轻微。结论:一线应用奈达铂联合多西紫杉醇治疗晚期肺鳞癌,耐受性好,有较好的临床应用价值。Objective： To evaluate the efficacy and safety of nedaplatin combined with docetaxel in the treatment of advanced lung squamous carcinoma. Methods： 21 patients with advanced lung squamous carcinoma,who never received chemotherapy,whose volumes of tumor could be measured,received docetaxel（ 60 mg/m^2） and nedaplatin（ 80 mg/m^2） treatment on the first day,every 3 weeks as a treatment course,for four courses altogether. Results： After the treatment with nedaplatin combined with cisplatin,the objective response rate was 62%. Median progression-free survival time was 7. 4 months,median survival time was 16.1 months,and one-year survival rate was 66.7%. The most common adverse reactions was neutropenia（ grade 3/4,86%） and relatively mild non-blood system toxicity. Conclusion：The clinical application of nedaplatin combined with docetaxel for advanced lung squamous carcinoma shows good tolerance,indicating good clinical application value for patients.

关 键 词：奈达铂 多西紫杉醇 晚期肺鳞癌 

分 类 号：R734.2[医药卫生—肿瘤]